FISCHER MEDICAL VENTURES LIMITED
Quarterly Results Announcement – 14 August 2025

• Financial Highlights (Q1 FY26 ended 30 June 2025):

  • Standalone revenue from operations: Rs. 454.23 Lakhs (down from Rs. 521.97 Lakhs in Q4 FY25)
  • Standalone loss before tax: Rs. (21.56) Lakhs (improved from Rs. (113.15) Lakhs in Q4 FY25)
  • Consolidated total income: Rs. 3,091.11 Lakhs
  • Consolidated profit before tax: Rs. 1,028.68 Lakhs
  • FY25 consolidated revenue: Rs. 11,069.87 Lakhs, up from Rs. 2,098.13 Lakhs in FY24
  • Standalone FY25 revenue: Rs. 521.97 Lakhs, down from Rs. 1,152.83 Lakhs in FY24

• Balance Sheet Items:

  • Consolidated total assets of subsidiaries as of 30 June 2025: Rs. 41,539.12 Lakhs

• Auditor’s Note:

  • Both standalone and consolidated results reviewed by M/s Bilimoria Mehta & Co. with unmodified opinion and no qualifications.

• Management Commentary:

  • No specific commentary or changes in accounting policies disclosed.
  • Resignation of Independent Director Dr. Jacob Thomas effective 14 August 2025.
  • Appointment of M/s Nuren Lodaya & Associates as Secretarial Auditors for five years.

• Segment and Corporate Activity:

  • No segment-wise financial details provided; consolidated results include multiple subsidiaries and associates across India, Philippines, Singapore, and Malaysia.
  • No capex, acquisitions, divestitures, or strategic initiatives reported.

• Outlook:

  • No guidance or outlook provided in the announcement.

Note: EPS and margin data were not disclosed; further details on profitability metrics and segment performance may be required.